Pancreatic Ductal Adenocarcinoma Clinical Trials in Madison, Wisconsin

5 studies are recruiting for pancreatic ductal adenocarcinoma in Madison, Wisconsin right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

   Locations

   48 in total

   Run by

   Immuneering Corporation

   See if you can join NCT07562152 on ClinicalTrials.gov

2. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

   Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surg…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293), Madison, Wisconsin

   Locations

   55 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06428409 on ClinicalTrials.gov

3. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

   The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin

   Locations

   52 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06586515 on ClinicalTrials.gov

4. Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

   This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for s…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin

   Locations

   11 in total

   Run by

   Phanes Therapeutics

   See if you can join NCT05482893 on ClinicalTrials.gov

5. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   University of Wisconsin, Madison, Wisconsin

   Locations

   11 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov